| Literature DB >> 33178771 |
Zhaoxiong Fang1, Zhiqiang Gu1, Tian Zhang2, Junjie Lei3, Lu Lin1, Zhixiang Yan4, Keke Feng5, Mengsha Xie6, Shuanshuan Guo2, Zhigang Liu2, Zhongsi Hong7, Xiaofeng Li1.
Abstract
BACKGROUND: More than 26,760,000 cases of SARS-CoV-2 infection have been reported globally to date. This study aimed to analyze the impact of new electronic communication tools in the diagnosis and treatment of patients with SARS-CoV-2 infection.Entities:
Keywords: Coronavirus disease 2019 (COVID-19); electronic communication tool; physician-patient communication; severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2 infection); therapy
Year: 2020 PMID: 33178771 PMCID: PMC7607116 DOI: 10.21037/atm-20-6413
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Demographic, clinical, and radiographic characteristics of 47 patients with SARS-CoV-2 infection on admission
| Variable | All patients (n=47) | Test group (n=14) | Control group (n=33) | P value |
|---|---|---|---|---|
| Characteristics | ||||
| Age, years | 36.0 (29.0–44.0) | 33.0 (28.8–45.8) | 36.0 (30.5–44.5) | 0.40 |
| Male | 21 (44.7) | 7 (50.0) | 14 (42.4) | 0.93 |
| Comorbidity | ||||
| Chronic obstructive pulmonary disease | 0 | 0 | 0 | |
| Diabetes | 1 (2.1) | 1 (7.1) | 0 | 0.33 |
| Hypertension | 2 (4.3) | 2 (14.3) | 0 | 0.10 |
| Coronary heart disease | 0 | 0 | 0 | |
| Cerebral vascular disease | 0 | 0 | 0 | |
| Hepatitis B | 0 | 0 | 0 | |
| Chronic kidney disease | 0 | 0 | 0 | |
| Incubation period | 6.0 (2.0–10.0) | 4.0 (1.0–11.3) | 6.0 (3.0–9.0) | 0.40 |
| Signs and symptoms | ||||
| Fever | 26 (55.3) | 9 (64.3) | 17 (51.5) | 0.53 |
| Cough | 11 (23.4) | 2 (14.3) | 9 (27.3) | 0.46 |
| Phlegm | 15 (31.9) | 4 (28.6) | 11 (33.3) | 1.00 |
| Hemoptysis | 0 | 0 | 0 | |
| Conjunctiva injection | 1 (2.1) | 0 | 1 (3.0) | 1.00 |
| Muscular soreness | 4 (8.5) | 0 | 4 (12.1) | 0.30 |
| Weakness | 4 (8.5) | 2 (14.3) | 2 (6.1) | 0.57 |
| Headache or dizzy | 6 (12.8) | 2 (14.3) | 4 (12.1) | 1.00 |
| Anorexia | 4 (8.5) | 3 (21.4) | 1 (3.0) | 0.073 |
| Diarrhea | 1 (2.1) | 1 (7.1) | 0 | 0.30 |
| Stuffy or runny nose | 8 (17.0) | 3 (21.4) | 5 (15.2) | 0.68 |
| Sore throat | 9 (19.1) | 2 (14.3) | 7 (21.2) | 0.70 |
| Nausea and vomiting | 2 (4.3) | 0 | 2 (6.1) | 1.00 |
| CT manifestation | 0.52 | |||
| Viral pneumonia | 29 (61.7) | 10 (71.4) | 19 (57.6) | |
| Non-viral pneumonia | 18 (38.3) | 4 (28.6) | 14 (42.4) | |
| Loss of leukocytes/lymphocytes in blood routine examination | 7 (14.9) | 3 (21.4) | 4 (12.1) | 0.41 |
Data are presented as median (interquartile range) and n (%).
Figure 1The duration of positive-to-negative conversion of SARS-CoV-2 RNA of 47 patients. This was defined as the time from a laboratory-confirmed positive SARS-CoV-2 RNA result to a laboratory-confirmed negative SARS-CoV-2 RNA result after two consecutive negative respiratory tract sample results. The interval between the two negative results must be more than 24 hours.
The duration of positive-to-negative conversion of SARS-CoV-2 among the groups
| Group | Duration of PTN | P value |
|---|---|---|
| Control ( | 10.0 (6.5–14.5) | |
| Test group | 7.0 (3.8–10.8) | 0.032 |
| 5-min group | 7.0 (5.5–13.0) | 0.45 |
| 10-min group | 3.0 (3.0–7.5) | 0.0065 |
| 10-min + 10-min group | 8.5 (4.8–16.0) | 0.56 |
| 5-min group ( | 7.0 (5.5–13.0) | |
| 10-min group | 3.0 (3.0–7.5) | 0.064 |
| 10-min + 10-min group | 8.5 (4.8–16.0) | >0.99 |
| 10-min group ( | 3.0 (3.0–7.5) | |
| 10-min + 10-min group | 8.5 (4.8–16.0) | 0.12 |
Data are presented as median (interquartile range). PTN, positive-to negative.